Skip to content

Chronic Hepatitis C

Chronic hepatitis C is a persistent liver infection caused by the hepatitis C virus (HCV). Unlike acute infection, which the body sometimes clears on its own, the chronic form persists for more than six months and can quietly damage the liver over years. HCV is a significant public health concern, and prevalence is particularly high among people who received blood products before widespread screening was introduced.

Natdac

Daclatasvir

60mg

Natdac is daclatasvir 60mg tablets for chronic hepatitis C, an NS5A inhibitor taken alongside a second direct-acting antiviral.

From$6.26/ tabletView

Harvoni

Ledipasvir, Sofosbuvir

90/400mg

Ledipasvir with sofosbuvir as a film-coated tablet, used in the management of chronic hepatitis C. An NS5A inhibitor paired with an NS5B polymerase inhibitor.

From$8.58/ tabletView

Sovaldi

Sofosbuvir

400mg

Sofosbuvir 400mg film-coated tablets, used in the management of chronic hepatitis C. An NS5B polymerase inhibitor that halts viral replication.

From$29.21/ tabletView

Rebetol

Ribavirin

200mg

Ribavirin at the 200mg hard capsule strength, used in the management of chronic hepatitis C alongside another antiviral. A nucleoside analogue.

From$5.26/ tabletView

Copegus

Ribavirin

100mg

Ribavirin 100mg film-coated tablets, used in the management of chronic hepatitis C. A nucleoside analogue that interferes with viral RNA replication.

From$4.86/ tabletView

Daklinza

Daclatasvir

60mg

Daclatasvir 60mg film-coated tablets, used in the management of chronic hepatitis C. An NS5A inhibitor blocking both RNA replication and virion assembly.

From$14.00/ tabletView

Velpanat

Sofosbuvir, Velpatasvir

400/100mg

Velpanat is sofosbuvir with velpatasvir 400/100mg for chronic hepatitis C, pairing a polymerase inhibitor with a replication complex inhibitor.

From$44.20/ tabletView

Key points

  • Modern direct-acting antivirals taken for eight to twelve weeks cure more than 95 percent of cases.
  • Sofosbuvir forms the backbone of many regimens, commonly paired with ledipasvir, velpatasvir or daclatasvir depending on the viral genotype.
  • Alcohol markedly speeds up liver fibrosis and is best avoided both before and during treatment.
  • Even after a confirmed cure, anyone who already had advanced fibrosis may still need ongoing liver surveillance, since cirrhosis carries lasting cancer risk.

How HCV damages the liver over time

The virus replicates inside liver cells, triggering ongoing inflammation. Most people have few or no symptoms for decades, which is why chronic hepatitis C is often found incidentally during routine blood tests. Over time, repeated inflammation can lead to fibrosis (scarring), cirrhosis, and in some cases hepatocellular carcinoma. A simple blood test confirms active infection; a liver stiffness scan or biopsy can assess how much fibrosis has already occurred.

Direct-acting antivirals: the modern treatment

Current treatment uses combinations of direct-acting antivirals (DAAs) taken orally for 8 to 12 weeks, with cure rates above 95 percent. Sofosbuvir is a backbone ingredient in many regimens, often paired with ledipasvir, velpatasvir, or daclatasvir. Ribavirin is added in certain harder-to-treat genotypes. Tenofovir disoproxil may be used where HCV and hepatitis B or HIV coinfection are present. These medicines fall within the broader antivirals category and have largely replaced older interferon-based regimens. The right combination depends on the HCV genotype and the degree of liver damage already present.

Life alongside treatment

Alcohol accelerates liver fibrosis significantly and should be avoided during, and ideally well before, treatment. Certain common medicines, including some herbal preparations, interact with DAAs, so it is worth reviewing everything taken regularly before starting a course. After a confirmed cure (undetectable viral load 12 weeks post-treatment), liver surveillance may still be recommended for anyone who had advanced fibrosis, as cirrhosis itself carries residual cancer risk even after the virus is gone.

Further reading